| Autor: |
Schill, Wolf-Bernhard, Comhaire, Frank, Hargreave, Timothy B., Gooren, L. J. G. |
| Zdroj: |
Andrology for the Clinician; 2006, p528-534, 7p |
| Abstrakt: |
The introduction of the phosphodiesterase type 5 inhibitors (PDE inhibitors) has been a major step forward in the treatment of erectile dysfunction (ED). Though efficacious and safe, 50% of men discontinue treatment, largely because other sexological issues have not been properly addressed. To predict onset and duration of action, insight into the pharmacokinetics of the PDE inhibitors is required. In men whose testosterone levels are low, testosterone substitution may booster the efficacy of PDE inhibitors.Before receiving PDE inhibitor the cardiovascular status of a patient must be assessed. The main action of testosterone is on the central nervous system. It improves libido and mood. Levels in the low-normal range suffice. Hyperprolactinaemia impairs sexual interest and leads to secondary ED. Dopamine agonists are the treatment of choice. Men with paraphilias may be treated with drugs that lower androgen action if the desire to act out their paraphilia is high. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
